4.6 Review

Update in the Percutaneous Management of Coronary Chronic Total Occlusions

期刊

JACC-CARDIOVASCULAR INTERVENTIONS
卷 11, 期 7, 页码 615-625

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2017.10.052

关键词

chronic total occlusion; percutaneous coronary intervention; stable coronary artery disease

资金

  1. Asahi Intecc
  2. ACIST Medical Systems
  3. Gilead
  4. The Medicines Company
  5. Boston Scientific
  6. Merck
  7. Osprey
  8. Biosensors

向作者/读者索取更多资源

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) has been rapidly evolving during recent years. With improvement in equipment and techniques, high success rates can be achieved at experienced centers, although overall success rates remain low. Prospective, randomized-controlled data regarding optimal use and indications for CTO PCI remain limited. CTO PCI should be performed when the anticipated benefit exceeds the potential risk. New high-quality studies of the clinical outcomes and techniques of CTO PCI are needed, as is the expansion of expert centers and operators that can achieve excellent clinical outcomes in this challenging patient and lesion subgroup. In the current review the authors summarize the latest publications in CTO PCI and provide an overview of the current state of the field. (c) 2018 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据